Maintain vision and improve ocular health
Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.
The lead program of Nicox’s ophthalmic pipeline, NCX 470, is in Phase 3 clinical development targeting glaucoma. Our ophthalmic pipeline also includes a candidate under preclinical evaluation for development in retinal conditions, NCX 1728, and a clinical-stage product candidate for dry eye disease licensed exclusively to a partner for the Chinese market, NCX 4251. We have two products which are commercialized in the U.S.; VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024% and ZERVIATE® (cetirizine ophthalmic solution) 0.24%, for use in patients with open-angle glaucoma and ocular allergic conjunctivitis. ZERVIATE is also commercialized in China.